long acting Injection [Design Issues]

posted by jag009  – NJ, 2020-04-21 21:06 (363 d 00:35 ago) – Posting: # 21342
Views: 848


» But if it is mentioned in monograph that half-life is 17 days following single dose and 46 days after multiple dose, then which half-life we should consider while designing multiple dose study? In the same monograph, it is also stated that steady state is achieved after 4th dose on injection.

Have you found out why the increase in half-life?


Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 10 (0 registered, 10 guests [including 1 identified bots]).
Forum time: Monday 21:41 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz